by Jordana Choucair | Sep 1, 2021 | Life Sciences
Two senior vaccine regulators at the FDA who helped lead its review of COVID-19 vaccine applications will leave the agency this fall. Their departures come as the agency remains without a permanent commissioner and could interrupt its work on COVID-19 vaccines. Dr....
by Jordana Choucair | Aug 31, 2021 | Life Sciences
The CDC’s Advisory Committee on Immunization Practices unanimously endorsed the full approval of Pfizer and BioNTech’s COVID-19 vaccine for Americans ages 16 and older. While the recommendation isn’t binding, CDC Director Dr. Rochelle Walensky is expected to accept...
by Jordana Choucair | Aug 30, 2021 | Life Sciences
Biogen Inc. is offering its costly new Alzheimer’s disease treatment to some patients for free amid uncertainty around whether Medicare will reimburse for the controversial drug. Biogen has begun to provide Florida’s First Choice Neurology with free-of-charge...
by Jordana Choucair | Aug 27, 2021 | Life Sciences
A Morning Consult article looks at states’ efforts to increase oversight and transparency around pharmacy benefit managers’ (PBMs) negotiations with drugmakers and pharmacies. This year, states have introduced more than 100 bills targeting PBMs, and in July, attorneys...
by Jordana Choucair | Aug 26, 2021 | Life Sciences
Pfizer and Moderna announced plans to seek additional FDA approvals for their respective COVID-19 vaccines. Pfizer said it will submit its application for a third dose of its vaccine for everyone ages 16 and older by the end of this week. Federal regulators are likely...
by webmaster | Aug 25, 2021 | Life Sciences
Johnson & Johnson said a second dose of its COVID-19 vaccine generated a strong immune response in a study, with antibody levels ninefold higher among those who got a second shot compared with one month after their first dose. The company said the data makes the...
Recent Comments